Forty Seven

Pionyr Immunotherapeutics

This company develops antibody therapeutics that modify the tumor microenvironment to treat cancer patients.

Cytospire Therapeutics

This company develops multispecific immune cell engager antibodies for cancer patients to enhance and direct immune system activity against solid tumours.

Bolt Biotherapeutics

This company develops immune-stimulating antibody conjugate therapies to treat patients with solid tumours by activating the innate and adaptive immune systems.

ALX Oncology

This clinical-stage biopharmaceutical company develops novel therapies to treat cancer patients by expanding the possibilities of immuno-oncology and antibody-drug conjugates.

Tacalyx

This company develops antibody-based therapeutics targeting tumour associated carbohydrate antigens for the treatment of solid tumours in cancer patients.

Jounce Therapeutics

This clinical-stage biopharmaceutical company develops immunotherapy treatments for cancer patients by using a platform that enables the immune system to attack tumours.

Compass Therapeutics

Compass Therapeutics develops antibody-based therapies for cancer patients by targeting the relationship between the immune system and tumour growth.

Epsilogen

This company develops immunoglobulin E and A based antibody therapeutics to treat patients with solid tumours and ovarian cancer.